PAVmed (NASDAQ:PAVM) reported quarterly losses of $(0.14) per share which missed the analyst consensus estimate of $(0.10) by 40 percent. This is a 7.69 percent decrease over losses of $(0.13) per share from the same period last year.
Why Are Zogenix’s Shares Gaining Today?
The FDA has granted Priority Review to Zogenix Inc's (NASDAQ: